Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia
Author
McCubrey, James A.
Date
2016-11-03
Citation:
APA:
McCubrey, James A.. (November 2016).
Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia.
Oncotarget,
(7:48), p.79842-79853. Retrieved from
http://hdl.handle.net/10342/9629
MLA:
McCubrey, James A..
"Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia". Oncotarget.
7:48. (79842-79853.),
November 2016.
May 17, 2022.
http://hdl.handle.net/10342/9629.
Chicago:
McCubrey, James A.,
"Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia," Oncotarget 7, no.
48 (November 2016),
http://hdl.handle.net/10342/9629 (accessed
May 17, 2022).
AMA:
McCubrey, James A..
Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia. Oncotarget.
November 2016;
7(48)
79842-79853. http://hdl.handle.net/10342/9629. Accessed
May 17, 2022.
Collections